Very Disappointed, page-14

I was right, see Page 25 below, BORR 57% vs 11% for Vervoy alone, and BMS needs help to 'stay in the game' for I/O combos...

Almost positive BMS will 'counter', I'd almost go 'all in' on that...

https://viralytics.com/wp-content/u...vestor-presentation-January-15-2017-FINAL.pdf

Vultures circling, and they're very hungry, look at the price action the last 12 mths, odd to say the very least (manipulated seems more poignant), and with money like this (below), I guess you can make things happen...

"From most to least, here’s the amount of cash drugmakers have to repatriate to the US as part of tax reform.

• Amgen – $US39 billion
• Gilead – $US32 billion
• Pfizer – $US22 billion
• Merck – $US20 billion
• J&J – $US14 billion
• AbbVie – $US10 billion
• Lilly – $US9 billion
• BMS – $US9 billion
• Celgene – $US9 billion
• Biogen – $US4 billion"

https://www.*.com.au/pharma-and-biotech-companies-with-capital-to-repatriate-2018-1?r=US&IR=T

ML